Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

PTEN function in normal and neoplastic growth.

Lionel M L Chow1, Suzanne J Baker

  • 1Department of Developmental Neurobiology, St Jude Children's Research Hospital, 332 North Lauderdale Street, Memphis, TN 38105, USA.

Cancer Letters
|January 18, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dominant clones leverage developmental epigenomic states to drive ependymoma.

Nature·2026
Same author

A review of diffuse hemispheric glioma, H3 G34-mutant disease development, DNA repair, microenvironment, and treatments on the horizon.

NPJ precision oncology·2025
Same author

Genetic modeling of ELP1-associated Sonic hedgehog medulloblastoma identifies MDM2 as a selective therapeutic target.

Cancer cell·2025
Same author

Glial Malignancies.

Cold Spring Harbor perspectives in biology·2024
Same author

Capmatinib is an effective treatment for MET-fusion driven pediatric high-grade glioma and synergizes with radiotherapy.

Molecular cancer·2024
Same author

Oncohistones and disrupted development in pediatric-type diffuse high-grade glioma.

Cancer metastasis reviews·2023
Same journal

Early-onset lung cancer: etiologic heterogeneity, genomic features, and age-informed clinical management.

Cancer letters·2026
Same journal

Talazoparib engages innate immune activation via PARP trapping-dependent cGAS/STING activation in Ewing Sarcoma.

Cancer letters·2026
Same journal

Corrigendum to "Elevated MMP10/13 mediated barrier disruption and NF-κB activation aggravate colitis and colon tumorigenesis in both individual or full miR-148/152 family knockout mice" [Cancer Lett. (2022) 31 529 53-69].

Cancer letters·2026
Same journal

Corrigendum to "PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer" [Cancer Lett. 598 (2024) 217112].

Cancer letters·2026
Same journal

Differential bioenergetic reprogramming driven by sorafenib reveals therapeutic vulnerabilities in biliary tract cancers.

Cancer letters·2026
Same journal

Transcriptomic-based molecular classification of ampullary adenocarcinoma.

Cancer letters·2026
See all related articles

The PTEN tumor suppressor regulates cell growth and survival. Its inactivation, common in cancers like glioblastoma, drives tumorigenesis through tissue-specific mechanisms, offering potential therapeutic targets.

Area of Science:

  • Molecular Biology
  • Oncology
  • Cell Signaling

Background:

  • The PTEN tumor suppressor is a key negative regulator of the PI3K/AKT signaling pathway.
  • This pathway controls fundamental cellular processes such as growth, survival, proliferation, and migration.
  • Dysregulation of the PI3K/AKT pathway, particularly PTEN alterations, is implicated in numerous human cancers.

Purpose of the Study:

  • To investigate the role of PTEN in regulating the PI3K/AKT signaling cascade.
  • To understand how PTEN inactivation contributes to tumorigenesis in a tissue-specific manner.
  • To identify mechanisms of PTEN loss that could lead to novel cancer therapies.

Main Methods:

  • Analysis of PTEN alterations in human tumor samples.
  • Utilizing animal models to study PTEN inactivation effects.

Related Experiment Videos

  • Investigating downstream signaling pathways affected by PTEN loss.

    • Main Results:

    • PTEN is the most frequently altered component of the PI3K pathway in human malignancies.
    • PTEN mutations are found in both hereditary and sporadic cancers, notably glioblastoma, prostate, and endometrial cancer.
    • Evidence suggests PTEN inactivation has distinct, tissue-specific consequences.

    Conclusions:

    • PTEN plays a critical role in preventing cancer by negatively regulating the PI3K/AKT pathway.
    • Understanding the tissue-specific downstream effectors of PTEN loss is crucial for cancer research.
    • Further elucidation of these mechanisms may pave the way for targeted cancer therapeutics.